CLAIMS

1. Use of at least one substance:

- which promotes the targeting of the PML protein towards the nuclear bodies and/or its stabilization; and/or

- which is chosen from the compounds of arsenic, the compounds having the same biological properties as arsenic, and caspase inhibitors and/or substrates;

in combination with the PML protein and/or with an agent inducing the overexpression of the PML protein;

for the manufacture of a medicament intended to induce the death of undesirable cells and/or stimulate an immune reaction, the administration of the said substance and the administration of the PML protein and/or of the said agent inducing the overexpression of the PML protein being simultaneous or sequential.

2. Use according to Claim 1, in which the said substance is arsenic trioxide.

3. Use according to Claim 1, in which the said substance is zVAD.

4. Use according to any one of Claims 1 to 3, in which the said agent inducing the overexpression of the PML protein is an interferon, such as α-, β- or γ-interferon.

5. Use of at least one substance chosen from the compounds of arsenic, the compounds having the same biological properties as arsenic, and the caspase inhibitors and/or substrates, in association with an interferon, for the manufacture of a medicament intended to induce the death of undesirable cells and/or stimulate an immune reaction, the administration of the said substance and the administration of the interferon being simultaneous or sequential.

6. Method *in vitro* for inducing the death of undesirable cells comprising bringing undesirable cells into contact with a substance chosen from the compounds

of arsenic, the compounds having the same biological properties as arsenic, and the caspase inhibitors and/or substrates, the said substance being associated with the PML protein and/or with an agent inducing the overexpression of the PML protein, preferably an interferon.

7. Pharmaceutical composition containing

1) either at least one caspase inhibitor and/or substrate combined with:

- at least one compound of arsenic or one compound having the same biological properties as arsenic;
- and/or the PML protein
- and/or at least one agent inducing the overexpression of the PML protein, such as an interferon;

in the presence of a pharmaceutically acceptable vehicle;

2) or at least one compound of arsenic or one compound having the same biological properties as arsenic, associated with the PML protein and/or with at least one agent inducing the overexpression of the PML protein, such as an interferon, in the presence of a pharmaceutically acceptable vehicle.

8. Kit comprising

a) - a pharmaceutical composition (1) containing at least one caspase inhibitor and/or substrate, in association with a pharmaceutically acceptable vehicle;

- and/or a pharmaceutical composition (2) containing at least one compound of arsenic or one compound having the same properties as arsenic, in association with a pharmaceutically acceptable vehicle; and

b) - a pharmaceutical composition (3) containing the PML protein in association with a pharmaceutically acceptable vehicle;

- and/or a pharmaceutical composition (4) containing at least one agent inducing the over-

expression of the PML protein, such as an interferon, in association with a pharmaceutically acceptable vehicle;

the said pharmaceutical compositions being intended for simultaneous or sequential administration.

9. Use of at least one substance, other than the compounds of arsenic, promoting the targeting of the PML protein towards the nuclear bodies and/or its stabilization, for the manufacture of a medicament intended to induce the death of undesirable cells, and/or stimulate an immune reaction.

10. Use of at least one substance chosen from caspase inhibitors and/or substrates for the manufacture of a medicament intended to induce the death of undesirable cells, and/or stimulate an immune reaction.

11. Use according to Claim 10, in which the said substance is zVAD.